SCHEMBL13619240

SCHEMBL13619240

C[C@H](C/C=C/C[C@H](C)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17787236 0.91 CTSK (0.31)
SCHEMBL15508198 0.90
SCHEMBL16940575 0.85 TRPA1 (0.31)
SCHEMBL2160578 0.83 APLNR (0.33)
SCHEMBL336375 0.83
SCHEMBL5633650 0.83 APLNR (0.33)
SCHEMBL9304034 0.83 APLNR (0.33)
SCHEMBL8157609 0.83
SCHEMBL15516197 0.82 HCAR2 (0.32)
SCHEMBL15516196 0.82 HCAR2 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615543-B2 Complexes with C-reactive protein (CRP) molecules; rheumatoid arthritis, juvenile chronic (rheumatoid) arthritis, ankylosing spondylitis, psoriatic arthritis, systemic vasculitis, polymyalgia rheumatica, Reiter's disease, Crohn's disease and familial Mediterranean fever PENTRAXIN THERAPEUTICS LIMITED (GB) 2009-11-10 US disclosed